Please login to the form below

Glybera

This page shows the latest Glybera news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

While enormously exciting gene therapy is still very much in its infancy, with just three commercial gene therapies approved in Europe and the US since UniQure’s Glybera made its debut

Latest news

UniQure’s starts pivotal haemophilia B gene therapy trial

UniQure has the distinction of being the first company to get approval for a gene therapy in Europe, winning a green light for its Glybera (alipogene tiparvovec) product for the
Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum

Another gene therapy, UniQure’s Glybera, was withdrawn from the market after it flopped commercially – in part because of the excessive cost of manufacturing it.
NICE backs GSK’s €594k gene therapy for rare disease

Strimvelis was approved by the EMA in 2016 - the second gene therapy to get a green light anywhere in the world after UniQure’s $1m Glybera (alipogene tiparvovec) product for lipoprotein
Spark’s Luxturna becomes US’s first approved gene therapy

UniQure charged $1m for its Glybera (alipogene tiparvovec) product for lipoprotein lipase deficiency (LPLD) - the first gene therapy approved in Europe - but that product was withdrawn from the market this year
Spark closes on first US gene therapy approval

The first (and so far only) gene therapy to reach the market in the EU - UniQure/Chiesi's 1m-per-treatment Glybera (alipogene tiparvovec) for lipoprotein lipase deficiency (LPLD) - was withdrawn

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Health on instalment

Before being pulled from the European market for safety concerns and lack of uptake, pancreatic drug Glybera cost $1m a dose.
Rare diseases: meeting the challenge

Glybera, the expensive gene therapy developed for a small subset of patients with the rare familial lipoprotein lipase deficiency (LPLD). ... The company’s chief executive Matthew Kapusta said simply: “Glybera’s usage has been extremely limited and
Pharma deals in April 2015

Following Glybera's approval in Europe for lipoprotein lipase deficiency (LPLD), uniQure, the gene therapy pioneer has announced an exclusive strategic collaboration with Bristol Myers Squibb (BMS) for its lead candidate ... Glybera's $1m cost per
Anticipating the future in healthcare

As a gene therapy, Glybera is injected through a one-time course of up to 60 consecutive intramuscular injections. ... The introduction of therapies such as Glybera and Holostem will have significant implications on the healthcare ecosystem.
Gathering pace: adaptive pathways

need for changes to its licensing framework in the wake of the approval last year of UniQure's gene therapy Glybera (alipogene tiparvovec) for lipoprotein lipase deficiency. ... Glybera was eventually approved for a narrower group of patients than

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Basilea's Hans Christian Rohde takes up commercial role at uniQure

In his new role at Netherlands-based uniQure he will be tasked with helping the company commercialise Glybera, which last month became the first gene therapy to be approved in the ... Glybera treats patients with the inherited disease lipoprotein lipase

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Delivery Manager/ Head of Delivery – Executive Search: Neg

Editorial Director – Medical Education (MedComms): Neg

Home based, Editorial Team Leader, Medical Communications: Excellent package

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Home based, Chief Medical Writer, Medical Communications: Excellent package

Healthcare PR Director: £100, 000 – £120, 000 benefits

Business Unit Head, Medical Communications, London: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Client Services Director – Healthcare Advertising - London: Neg

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Home based, Principal Medical Writer, Medical Communications: Excellent package

Home based, Senior Medical Writer, Medical Communications: Excellent package

Senior Account Manager: Competitive salary commensurate with experience

Client Services Director - Med Comms: Great salary and bebefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Subscribe to our email news alerts

PMHub

Add my company

OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....